The Lancet The Lancet, Elsevier, 2019, 394 (10204), pp.1169-1180. ⟨10.1016/S0140-6736(19)31887-2⟩ The Lancet (London), 394, 1169-1180 Bhatt, D L, Steg, P G, Mehta, S R, Leiter, L A, Simon, T, Fox, K, Held, C, Andersson, M, Himmelmann, A, Ridderstråle, W, Chen, J, Song, Y, Diaz, R, Goto, S, James, S K, Ray, K K, Parkhomenko, A N, Kosiborod, M N, McGuire, D K, Harrington, R A & THEMIS Steering Committee and Investigators 2019, ' Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial ', Lancet, vol. 394, no. 10204, pp. 1169-1180 . https://doi.org/10.1016/S0140-6736(19)31887-2 The Lancet (London), 394, 10204, pp. 1169-1180
Dart, A E, Worth, D C, Muir, G, Chandra, A, Morris, J D, McKee, C, Verrill, C, Bryant, R J & Gordon-Weeks, P R 2017, ' The drebrin/EB3 pathway drives invasive activity in prostate cancer ', Oncogene, vol. 36, no. 29, pp. 4111–4123 . https://doi.org/10.1038/onc.2017.45 Oncogene
New England Journal of Medicine New England Journal of Medicine, Massachusetts Medical Society, 2013, 369 (22), pp.2093-104. ⟨10.1056/NEJMoa1310907⟩ New England journal of medicine, 369(22), 2093-2104. Massachussetts Medical Society The New England Journal of Medicine, 369, 2093-104 The New England Journal of Medicine, 369, 22, pp. 2093-104